March 21, 2025

Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression

HEIDELBERG, Germany, March 06, 2024 – Hummingbird Diagnostics GmbH, a leader in using blood-based small RNAs for early disease detection and characterization, today announced a publication in Scientific Data, a peer-reviewed, open-access journal launched by Nature. The study evaluated miR-Blood, Hummingbird Diagnostics’ small RNA expression dataset for eleven major components of human peripheral blood.

A highly comprehensive blood cell type expression atlas for small RNAs, miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression, enabling a deeper understanding of blood and immune biology. The findings detailed in this publication demonstrate miR-Blood atlas’ ultra-deep expression profiling ability for plasma as well as ten cell populations.

“This study yields additional insights into the source of origin of our previously discovered lung cancer biomarker signature, previously published in the Journal of Thoracic Oncology. This further supports Hummingbird’s approach of merging the analysis of tumor-derived and immune system-derived small RNA biomarkers,” remarked Dr. Rastislav Horos, Chief Technology Officer of Hummingbird Diagnostics. “We look forward to continuing the development of miR-Blood and we believe in its potential impact on research into small RNA expression and biomarker discovery.” The miR-Blood atlas contains expression data for 4971 small RNAs, attributed to eight non-coding RNA classes including miRNAs and tRNAs, and is freely available online via a user friendly and interactive dashboard: https://mir-blood.com/.

About Hummingbird Diagnostics GmbH

Hummingbird extracts deep insights into disease through the integrated analysis of both tumor and immune system derived small RNA biomarkers from whole blood.

This dual interrogation of signal from disease and the host response to disease enables the highly sensitive, robust, and AI powered mirCator platform that is poised to revolutionize how we diagnose, treat, and manage cancer and other diseases. 

Our latest News

discover more
Workflow Optimisation in the Laboratory: Premiere of the smartLabs Summit in Heidelberg

Workflow Optimisation in the Laboratory: Premiere of the smartLabs Summit in Heidelberg

On September 24, 2025, the smartLabs Summit will open its doors for the first time in Heidelberg – an event dedicated to practical innovation, digitalization, and automation in laboratories. The Summit will take place at BioLabs Heidelberg (Nicola-Tesla Straße 1–3, 69124 Heidelberg) and offers a full program from 1:00 to 7:30 p.m. Initiated by the […]

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

The aim of the project is to use special quantitative MRI to visualize early changes in the intervertebral disc and enable timely treatment. Ultrashort echo time (UTE) MRI opens up completely new approaches to preventive imaging that are difficult or impossible to achieve with conventional MRI methods. Full text in German below. DFG fördert Heidelberger […]

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Researchers from Heidelberg University’s Medical Faculty, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases (NCT) in Heidelberg have tested the use of targeted drugs in the initial treatment of newly diagnosed glioblastoma, an extremely aggressive brain tumor, in the multicenter study “NCT Neuro Master Match (N2M2)”. Of the five drugs […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp